Story perspectives

Breakthrough Drug ION224 Shows Promise Against Liver Disease

9/15/2025

37 2

Summary

Story summary

Researchers at UC San Diego created ION224, a drug targeting metabolic dysfunction-associated steatohepatitis (MASH), linked to obesity and diabetes.
ION224 inhibits the DGAT2 enzyme, decreasing liver fat accumulation and inflammation.
In a Phase IIb trial, 60% of patients on the highest dose showed significant liver health improvements.
MASH affects over 100 million people in the U.S. and can lead to severe liver conditions if untreated.
A larger clinical trial is planned to confirm these findings and explore targeted therapy options.

1 of 1

Story summary

Researchers at UC San Diego created ION224, a drug targeting metabolic dysfunction-associated steatohepatitis (MASH), linked to obesity and diabetes.
ION224 inhibits the DGAT2 enzyme, decreasing liver fat accumulation and inflammation.
In a Phase IIb trial, 60% of patients on the highest dose showed significant liver health improvements.
MASH affects over 100 million people in the U.S. and can lead to severe liver conditions if untreated.
A larger clinical trial is planned to confirm these findings and explore targeted therapy options.